The data include the principal molecular mechanisms and functional outcomes. Aβ: amyloid-beta; AD: Alzheimer’s disease; BDNF: brain-derived neurotrophic factor; CAT: catalase; CPC: C-Phycocyanin; CYBB: cytochrome b-245 beta chain; EAE: experimental autoimmune encephalomyelitis; HO-1: heme oxygenase-1; IFN-γ: interferon-γ; IL-6: interleukin-6; MS: multiple sclerosis; NOX2: nicotinamide adenine dinucleotide phosphate oxidase 2; PCB: phycocyanobilin; SOD2: superoxide dismutase 2; TNF-α: tumor necrosis factor-alpha. The arrow pointing upwards (↑) represents an increase, and the arrow pointing downwards (↓) represents a decrease.
Declarations
Acknowledgments
We thank Dr. Ania Cabrales-Rico and Osmany Guirola-Cruz for their technical assistance with the images, which was essential for the successful completion of this manuscript. The authors acknowledge the use of ChatGPT (OpenAI, San Francisco, CA, USA) to assist in improving the readability of the manuscript. All content was critically reviewed and approved by the authors, who take full responsibility for the publication.
Author contributions
SDL and YRÁ: Methodology, Writing—original draft, Formal analysis. GPR: Supervision, Methodology, Writing—review & editing. All authors read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
Fornari A, Lanza M, Guastafierro E, Marcassoli A, Sismondo P, Curatoli C, et al. Inequities in neurological care: Access to services, care gaps, and other barriers-A systematic review.Eur J Neurol. 2025;32:e16553. [DOI] [PubMed] [PMC]
Erickson MA, Dohi K, Banks WA. Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier.Neuroimmunomodulation. 2012;19:121–30. [DOI] [PubMed] [PMC]
Picca A, Calvani R, Coelho-Junior HJ, Landi F, Bernabei R, Marzetti E. Mitochondrial Dysfunction, Oxidative Stress, and Neuroinflammation: Intertwined Roads to Neurodegeneration.Antioxidants (Basel). 2020;9:647. [DOI] [PubMed] [PMC]
Marín-Prida J, Rodríguez-Ulloa A, Besada V, Llopiz-Arzuaga A, Batista NV, Hernández-González I, et al. The effects of Phycocyanobilin on experimental arthritis involve the reduction in nociception and synovial neutrophil infiltration, inhibition of cytokine production, and modulation of the neuronal proteome.Front Immunol. 2023;14:1227268. [DOI] [PubMed] [PMC]
Marín-Prida J, Pavón-Fuentes N, Lagumersindez-Denis N, Camacho-Rodríguez H, García-Soca AM, Sarduy-Chávez RC, et al. Anti-inflammatory mechanisms and pharmacological actions of phycocyanobilin in a mouse model of experimental autoimmune encephalomyelitis: A therapeutic promise for multiple sclerosis.Front Immunol. 2022;13:1036200. [DOI] [PubMed] [PMC]
Ye Z, Fang J, Yao B, Liu G. Heterologous Expression of Phycocyanobilin in Escherichia coli and Determination of Its Antioxidant Capacity In Vitro.Mol Biotechnol. 2025;67:983–95. [DOI] [PubMed]
Minic SL, Milcic M, Stanic-Vucinic D, Radibratovic M, Sotiroudis TG, Nikolic MR, et al. Phycocyanobilin, a bioactive tetrapyrrolic compound of blue-green alga Spirulina, binds with high affinity and competes with bilirubin for binding on human serum albumin.RSC Advances. 2015;5:61787–98. [DOI]
Jansen T, Daiber A. Direct Antioxidant Properties of Bilirubin and Biliverdin. Is there a Role for Biliverdin Reductase?Front Pharmacol. 2012;3:30. [DOI] [PubMed] [PMC]
McCarty MF. Clinical potential of Spirulina as a source of phycocyanobilin.J Med Food. 2007;10:566–70. [DOI] [PubMed]
Pentón-Rol G, Marín-Prida J, McCarty MF. C-Phycocyanin-derived Phycocyanobilin as a Potential Nutraceutical Approach for Major Neurodegenerative Disorders and COVID-19- induced Damage to the Nervous System.Curr Neuropharmacol. 2021;19:2250–75. [DOI] [PubMed] [PMC]
Ge B, Li Y, Sun H, Zhang S, Hu P, Qin S, et al. Combinational biosynthesis of phycocyanobilin using genetically-engineered Escherichia coli.Biotechnol Lett. 2013;35:689–93. [DOI] [PubMed]
Tooley AJ, Cai YA, Glazer AN. Biosynthesis of a fluorescent cyanobacterial C-phycocyanin holo-alpha subunit in a heterologous host.Proc Natl Acad Sci U S A. 2001;98:10560–5. [DOI] [PubMed] [PMC]
Cervantes-Llanos M, Lagumersindez-Denis N, Marín-Prida J, Pavón-Fuentes N, Falcon-Cama V, Piniella-Matamoros B, et al. Beneficial effects of oral administration of C-Phycocyanin and Phycocyanobilin in rodent models of experimental autoimmune encephalomyelitis.Life Sci. 2018;194:130–8. [DOI] [PubMed]
Gardón DP, Cervantes-Llanos M, Matamoros BP, Rodríguez HC, Tan CY, Marín-Prida J, et al. Positive effects of Phycocyanobilin on gene expression in glutamate-induced excitotoxicity in SH-SY5Y cells and animal models of multiple sclerosis and cerebral ischemia.Heliyon. 2022;8:e09769. [DOI] [PubMed] [PMC]
Pentón-Rol G, Martínez-Sánchez G, Cervantes-Llanos M, Lagumersindez-Denis N, Acosta-Medina EF, Falcón-Cama V, et al. C-Phycocyanin ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells.Int Immunopharmacol. 2011;11:29–38. [DOI] [PubMed]
Pentón-Rol G, Marín-Prida J, Falcón-Cama V. C-Phycocyanin and Phycocyanobilin as Remyelination Therapies for Enhancing Recovery in Multiple Sclerosis and Ischemic Stroke: A Preclinical Perspective.Behav Sci (Basel). 2018;8:15. [DOI] [PubMed] [PMC]
Marín-Prida J, Pavón-Fuentes N, Llópiz-Arzuaga A, Fernández-Massó JR, Delgado-Roche L, Mendoza-Marí Y, et al. Phycocyanobilin promotes PC12 cell survival and modulates immune and inflammatory genes and oxidative stress markers in acute cerebral hypoperfusion in rats.Toxicol Appl Pharmacol. 2013;272:49–60. [DOI] [PubMed]
Pavón-Fuentes N, Marín-Prida J, Llópiz-Arzuaga A, Falcón-Cama V, Campos-Mojena R, Cervantes-Llanos M, et al. Phycocyanobilin reduces brain injury after endothelin-1-induced focal cerebral ischaemia.Clin Exp Pharmacol Physiol. 2020;47:383–92. [DOI] [PubMed]
Marín-Prida J, Liberato JL, Llópiz-Arzuaga A, Stringhetta-Padovani K, Pavón-Fuentes N, Leopoldino AM, et al. Novel Insights into the Molecular Mechanisms Involved in the Neuroprotective Effects of C-Phycocyanin against Brain Ischemia in Rats.Curr Pharm Des. 2022;28:1187–97. [DOI] [PubMed]
Matamoros BP, Prida JM, Rol GP. Nutraceutical and therapeutic potential of Phycocyanobilin for treating Alzheimer’s disease.J Biosci. 2021;46:42. [PubMed]
Choi WY, Kang DH, Lee HY. Effect of Fermented Spirulina maxima Extract on Cognitive-Enhancing Activities in Mice with Scopolamine-Induced Dementia.Evid Based Complement Alternat Med. 2018;2018:7218504. [DOI] [PubMed] [PMC]
Ghanbari A, Vafaei AA, Naghibi nasab FS, Attarmoghaddam M, Bandegi AR, Moradi-Kor N. Spirulina microalgae improves memory deficit induced by scopolamine in male pup rats: Role of oxidative stress.S Afr J Bot. 2019;127:220–5. [DOI]
Agrawal M, Perumal Y, Bansal S, Arora S, Chopra K. Phycocyanin alleviates ICV-STZ induced cognitive and molecular deficits via PI3-Kinase dependent pathway.Food Chem Toxicol. 2020;145:111684. [DOI] [PubMed]
Lai MC, Liu WY, Tzeng YC, Liu IM. Algae-derived C-phycocyanin mitigates AGE-RAGE-induced ER stress and mitochondrial apoptosis: Implications for diabetes-associated neurodegeneration.Int J Mol Sci. 2025;26:11077. [DOI] [PubMed] [PMC]
Sedlak TW, Saleh M, Higginson DS, Paul BD, Juluri KR, Snyder SH. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles.Proc Natl Acad Sci U S A. 2009;106:5171–6. [DOI] [PubMed] [PMC]
Romay C, González R, Ledón N, Remirez D, Rimbau V. C-Phycocyanin: a biliprotein with antioxidant, anti-inflammatory and neuroprotective effects.Curr Protein Pept Sci. 2003;4:207–16. [DOI] [PubMed]
Li Y. The Bioactivities of Phycocyanobilin from Spirulina.J Immunol Res. 2022;2022:4008991. [DOI] [PubMed] [PMC]
Pagels F, Guedes AC, Amaro HM, Kijjoa A, Vasconcelos V. Phycobiliproteins from cyanobacteria: Chemistry and biotechnological applications.Biotechnol Adv. 2019;37:422–43. [DOI] [PubMed]
Dagnino-Leone J, Figueroa CP, Castañeda ML, Youlton AD, Vallejos-Almirall A, Agurto-Muñoz A, et al. Phycobiliproteins: Structural aspects, functional characteristics, and biotechnological perspectives.Comput Struct Biotechnol J. 2022;20:1506–27. [DOI] [PubMed] [PMC]
Wang Z, Zhou J, Li J, Du G, Chen J, Zhao X. Rational Design of Key Enzymes to Efficiently Synthesize Phycocyanobilin in Escherichia coli.Biomolecules. 2024;14:301. [DOI]
Esclapez J, Matarredona L, Zafrilla G, Camacho M, Bonete MJ, Zafrilla B. Optimization of Phycocyanobilin Synthesis in E. coli BL21: Biotechnological Insights and Challenges for Scalable Production.Genes (Basel). 2024;15:1058. [DOI] [PubMed] [PMC]
GRAS Notice No.Arthrospira maxima. 2012.
ICH Expert Working Group. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3 (R2). International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use; 2009.
El Gaamouch F, Chen F, Ho L, Lin HY, Yuan C, Wong J, et al. Benefits of dietary polyphenols in Alzheimer’s disease.Front Aging Neurosci. 2022;14:1019942. [DOI] [PubMed] [PMC]
